Kiniksa Pharmaceuticals International (KNSA) Change in Account Payables (2017 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has reported Change in Account Payables for 10 consecutive years, with -$12.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Change in Account Payables fell 273.15% year-over-year to -$12.0 million; the trailing twelve-month figure through Jun 2026 stood at $3.4 million (up 111.06% YoY), and the FY2025 full-year result was $142000.0, up 102.25% from the prior year.
• Change in Account Payables eased to -$12.0 million in Q2 2026 per KNSA's latest filing, from $22.3 million in the prior quarter.
• Across five years, Change in Account Payables topped out at $22.3 million in Q1 2026 and bottomed at -$12.0 million in Q2 2026.
• Historically, Change in Account Payables has averaged $582277.8 across 5 years, with a median of -$340500.0 in 2023.
• The sharpest annual moves came in 2023 and 2026: Change in Account Payables tumbled 529.57% in 2023, then surged 35812.9% in 2026.
• Over 5 years, Change in Account Payables stood at $6.4 million in 2022, then gained by 12.5% to $7.2 million in 2023, then tumbled by 186.87% to -$6.3 million in 2024, then soared by 34.4% to -$4.1 million in 2025, then sank by 191.1% to -$12.0 million in 2026.
• According to Business Quant data, Change in Account Payables over the past three periods registered -$12.0 million, $22.3 million, and -$4.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.